×
AllNewsImagesVideos Maps Shopping Books
Search tools
Did you mean: Cerenia

Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims

Fierce Biotech
Abionyx Pharma has hailed the success of a phase 2a clinical trial designed to resurrect a cholesterol drug that first flamed out almost a...
15 months ago

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Labiotech.eu
Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic,...
115 months ago

Novasep's Outstanding Results in Scale-up and Biomanufacturing of Apo-A1 Acknowledged by Cerenis at BPI ...

Technology Networks
Cerenis to present manufacturing data for this biopharmaceutical against atherosclerotic cardiovascular disease at BPI conference in Prague,...
144 months ago

Evoq Therapeutics catches the eye of big pharma

Crain's Detroit Business
Evoq Therapeutics LLC, a pharmaceutical company spun off from the University of Michigan in 2016, has a motto: Been there, done that.
65 months ago

Where are they now? Tracking down 2011's Fierce 15

Fierce Biotech
While the Fierce Biotech team evaluates the most innovative biotechs worthy of the 2021 Fierce 15, it's time to check in with the class of...
31 months ago

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Labiotech.eu
Cerenis therapeutic's lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome.
85 months ago

Ann Arbor-based Evoq replaces CEO

Crain's Detroit Business
A week after signing a lucrative licensing agreement, the top management at Ann Arbor-based pharmaceutical startup Evoq Therapeutics Inc.
15 months ago

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

PMLiVE
Former GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage...
100 months ago